Antioxidants May Be Harmful in Patients With Melanoma
the ONA take:
Antioxidants may double the rate of metastasis in malignant melanoma, a study published in the journal Science Translational Medicine has shown.
Because melanoma cells are especially sensitive to free radicals, which can be neutralized by antioxidants, and the cells can be exposed to antioxidants through means other than diet, researchers from Sahlgrenska Academy at the University of Gothenburg in Sweden sought to evaluate the effect of antioxidants on cell cultures from patients with malignant melanoma.
The researchers found that although antioxidants protect healthy cells from free radicals that can potentially transform them into malignancies, they may also protect the tumor.
Results showed that the antioxidant enhanced the tumor’s ability to metastasize; however, the primary melanoma tumor was unaffected.
“Previous research as Sahlgrenska Academy has indicated that cancer patients are particularly prone to take supplements containing antioxidants.
Our current research combined with information from large clinical trials with antioxidants suggest that people who have been recently diagnosed with cancer should avoid supplements,” the authors conclude.
Antioxidants may double the rate of metastasis in malignant melanoma.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|